An unfavorable judgment amounting about $15.93 million in litigation involving a group of franchisees in Canada led Dunkin’ Brands (NASDAQ:DNKN) to announce a higher legal reserve in its Q2 compared to the earlier reserve held for $3.88 million.
Barron’s posted a weekend view that 3D held promise beyond being just a fad, and that there is a real trend for studios to now offer 3D versions of movies other than the action adventure genre. RealD (NYSE:RLD) could benefit from this view considering it invests close to $10,000 per theatre to instal 3D in return for a percentage for each 3D ticket sold thereafter.
Delta Air Lines’ (NYSE:DAL) unconventional move to trim fuel costs by buying up its own refinery is becoming a reality as subsidiary Monroe Energy commences maintenance procedures on the plant over the coming weeks in preparation for a likely fuel production date in the fall.
Credit Suisse (NYSE:CS) is countering Moody’s rating cut of 3 notches by advancing its plans to boost capital by issuing $6.3 billion of convertible bonds. The board continues to repose faith in CEO Brady Dougan, as, according to a source, “there’s no one better.”
Lexicon Pharmaceuticals’ (NASDAQ:LXRX) oral diabetes type 2 drug, LX4211, posted good results in a Phase 2b trial along with metformin – average blood glucose levels fell compared to a placebo. A phase 3 study of the drug is planned in H1 of 2013.